Cargando…

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yazbeck, R., Jaenisch, S.E., Abbott, C.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954778/ https://www.ncbi.nlm.nih.gov/pubmed/33722535 http://dx.doi.org/10.1016/j.bcp.2021.114517

Ejemplares similares

Development of a (13)C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity
por: Yazbeck, Roger, et al.
Publicado: (2019)

Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
por: Jaenisch, Simone E., et al.
Publicado: (2022)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
por: Shao, Shiying, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
por: Roy, Ayan, et al.
Publicado: (2021)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors
por: Khalse, Maneesha, et al.
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
por: Daza-Arnedo, Rodrigo, et al.
Publicado: (2021)

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
por: Richter, Bernd, et al.
Publicado: (2008)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
por: Lim, Sun Woo, et al.
Publicado: (2015)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
por: Cao, Fen, et al.
Publicado: (2021)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Collagenous Colitis Possibly Associated with Dipeptidyl Peptidase-4 Inhibitor
por: Takedomi, Hironobu, et al.
Publicado: (2022)

Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19
por: Chen, Chun-Fan, et al.
Publicado: (2020)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
por: Cox, Mary Elizabeth, et al.
Publicado: (2010)

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

Synergistic effect of α‐glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment
por: Horikawa, Yukio, et al.
Publicado: (2010)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid()()
por: Gravani, Agoritsa, et al.
Publicado: (2021)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
por: Florentin, Matilda, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
por: Narayanan, Niya, et al.
Publicado: (2022)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
por: Gurgel Penaforte-Saboia, Jaquellyne, et al.
Publicado: (2021)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
por: Shaikh, Sibhghatulla, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ghrmceefs5d63vbr0ol9bq89l